Upadacitinib Outcomes in High Risk RA Patients A safety analysis of six phase III SELECT trials showed that higher-risk RA patients had an increased risk of MACE, malignancy (excluding NMSC) and VTE regardless of being treated with either UPA or ADA. https://t.co/7JXntIV09K https://t.co/CthPcu2Ohs